goals of treatment in gastroparesis are to reduce symptoms, to maintain a sufficient nutritional state and an optimal weight
with respect to people with diabetes
NICE suggest (1):
a clinician should consider the diagnosis of gastroparesis in an adult with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into consideration possible alternative diagnoses
for adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that:
there is no strong evidence that any available antiemetic therapy is effective
some people have had benefit with domperidone, erythromycin or metoclopramide
the strongest evidence for effectiveness is for domperidone, but prescribers must take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines
to treat vomiting caused by gastroparesis in adults with type 2 diabetes:
consider alternating the use of erythromycin and metoclopramide
consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance on domperidone
if gastroparesis is suspected, consider referral to specialist services if:
differential diagnosis is in doubt, or
persistent or severe vomiting occurs
diet and lifestyle (2,3)
dietary measures are important in the management of gastroparesis
little or no evidence is available that dietary measures work, as they have not been studied in a controlled manner
advice should be targeted at individual intolerances or difficulties with specific food products. Especially, fat-rich items and late evening meals should be avoided. Referral to a dietitian may prove helpful
carbonated liquids should be avoided to limit gastric distention. Patients are instructed to take fluids throughout the course of the meal and to sit or walk for 1-2 hours after meals.
dietary and lifestyle advice should at least include the following recommendations:
reduce the number of fatty food products,
eat smaller portions more frequently during the day,
remain in an upright position during and after the course of a meal,
limit the intake of insoluble fibres,
stop smoking, although it should be noted that smoking itself triggers the gastrocolonic reflex and accelerates intestinal transit,
screen for deficiencies, especially in patients with weight loss and malnutrition and use multivitamin and/or vitamin supplementation, when needed
in cases with severe weight loss or inadequate nutrient intake, enteral feeding through a nasoduodenal tube should be considered
prokinetics
no medicines are licensed as prokinetics in the UK (4)
first-line prokinetic medicines are metoclopramide and domperidone
metoclopramide is approved in the United States for diabetic gastroparesis
domperidone is approved in Canada for gastrointestinal motility disorders associated with gastritis and diabetic gastroparesis
erythromycin is a second-line option.
other options include prucalopride and cisapride (discontinued in the UK
metoclopramide and domperidone
metoclopramide, a dopamine D2 receptor antagonist
both antiemetic and prokinetic properties
antiemetic effect of metoclopramide is based on the blockade of dopamine D2 receptors in the area postrema, located outside the blood-brain barrier, and the vomiting centre
prokinetic effect of metoclopramide is based on the blockade of dopamine D2 receptors in the gastrointestinal tract. Dopamine is known to cause inhibition of motility throughout the gastrointestinal tract. It reduces gastric tone and intragastric pressure and decreases antroduodenal coordination through activation of dopamine D2 receptors
metoclopramide not only shows dopamine D2 receptor antagonist properties but also shows moderate 5-hydroxytryptamine-4 (5HT4) agonist and 5HT3 antagonist properties
the US Food and Drug Administration (FDA) advises an adult oral dose of 10mg metoclopramide up to 4 times a day for reduced gastric motility (4)
is given 15-30 minutes before meals and at bedtime
is usually given for 2-8 weeks depending on how well symptoms are being controlled
the maximum recommended duration of treatment is 12 weeks due to the risk of extrapyramidal side effects such as tremor, muscle spasms and involuntary facial movements
domperidone, structurally related to butyrophenones, is also a dopamine D2 receptor antagonist
has similar effects as metoclopramide; however, it does not cross the blood-brain barrier and thus has a slightly less antiemetic effect
Health Canada advises an oral dose of 10mg domperidone 3 times a day (4)
the dose should be taken 15-30 minutes before meals
MHRA restrict use to a maximum of 7 days' duration due to the risk of QT prolongation
both metoclopramide and domperidone may induce hyperprolactinaemia
erythromycin
a macrolide antibiotic that is also a motilin receptor agonist
intravenous form is the most potent stimulant of solid and liquid gastric emptying
motilin is a polypeptide hormone present in the distal stomach and duodenum that increases lower oesophagal sphincter pressure and is responsible for initiating the migrating motor complexes (MMC) in the antrum of the stomach
enhances gastric emptying, increases antral contractions and antroduodenal coordination but reduces fundic volume and compliance in health and disease
oral administration of erythromycin is the preferred route for chronic use in patients with gastroparesis
the liquid form of erythromycin may be of additional benefit in gastroparesis, as it does not need to be disintegrated in the stomach
the standard dose of oral erythromycin is 250 to 500mg 3 times a day taken before meals (4)
the maximum dose is 500mg 4 times a day taken before meals and at bedtime.
erythromycin can also be started at a lower dose of 50 to 100mg 4 times a day and titrated to effect
starting at a lower dose reduces the risk of tachyphylaxis, which is a sudden decrease in efficacy and loss of symptom control
unfortunately, long-term use is limited because of its antibacterial effect and bacterial resistance, and occurrence of desensitization to the therapeutic prokinetic effect
other specialist interventions include:
intrapyloric botulinum toxin injection, gastric pacing or more radical surgical interventions, such as partial or total gastrectomy.
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page